Altria (MO) reached a new 52-week high on Tuesday, touching $76.17 before last trading around $76.48, above its previous close of $72.89. The stock is up 30.45% year to date and has gained 32.55% over the past year.

The move followed a stronger-than-expected earnings report. Altria posted earnings per share of $1.32, beating the consensus estimate of $1.25. Revenue came in at $4.76 billion, up 5.3% year over year and above analyst expectations of $4.58 billion.

For full-year 2026, the company guided for adjusted EPS of $5.56 to $5.72. Analysts currently expect $5.70 for the year, putting the new guidance in line with the Street’s current view.

Dividend Remains a Key Factor

Altria paid a quarterly dividend of $1.06 per share on July 10, equal to an annualized payout of $4.24 and a yield of about 5.5%.

The company has maintained its dividend for 56 consecutive years. Its payout ratio is 88.7%, which is high, but the income profile continues to appeal to yield-focused investors.

In May, two directors sold shares. Debra J. Kelly sold 5,790 shares at $72.25, reducing her position by 7.27%. Ellen R. Strahlman sold 2,000 shares at $72.56, a reduction of 7.38%. Both transactions were disclosed in SEC filings.

Institutional investors hold 57.41% of Altria shares. Several funds added to positions in recent quarters, including Bernardo Wealth Planning, which increased its stake by 4.6% in the second quarter.

Analyst Views Remain Mixed

The consensus analyst rating on MO is “Hold,” with an average price target of $70.78, below the stock’s current trading level.

UBS has a Buy rating with a $79 price target. Bank of America adjusted its estimates after favorable regulatory changes in the tobacco sector in the second quarter. BTIG initiated coverage in July with a Neutral rating. Citigroup raised its target from $65 to $70 and kept a Neutral rating. Morgan Stanley has a $71 target, while Jefferies rates the stock Underperform with a $60 target.

Among the 12 analysts covering Altria, five rate it Buy, five Hold, and two Sell.

The FDA recently proposed a rule requiring foreign tobacco manufacturers to register their facilities, a move viewed as favorable for domestic producers such as Altria. According to Bank of America data, oral tobacco sales grew through late May, while cigarette and vapor sales declined, underscoring the company’s exposure to shifting demand across tobacco categories.

Altria has a market capitalization of $127.82 billion, a price-to-earnings ratio of 16.01, and a beta of 0.45. Its 50-day moving average is $71.90, and its 200-day moving average is $67.95.